Sabon Madadin Drug Zai Iya Dakatar da Sel daga Hare Mai watsa shiri

Masu bincike sun ce dashen kwayoyin halitta, musamman daga ’yan gida daya, ya canza maganin cutar sankarar bargo, cutar da ke addabar Amurkawa kusan rabin miliyan. Kuma ko da yake maganin ya yi nasara ga mutane da yawa, rabin waɗanda aka yi wa aikin sun fuskanci wasu nau'i na cututtuka na graft-versus-host (GvHD). Wannan yana faruwa ne lokacin da sabbin ƙwayoyin rigakafi da aka dasa suka gane jikin mai masaukinsu a matsayin “baƙon waje” sannan suka yi niyya don kai hari, kamar dai cutar da ke mamayewa.

Yawancin lokuta na GvHD ana iya magance su, amma kiyasin ɗaya cikin 10 na iya zama barazanar rai. Don haka, masu bincike sun ce, ana amfani da magungunan da ke hana garkuwar jiki don hana GvHD ta sel da aka ba da gudummawa, kuma marasa lafiya, waɗanda galibi ba su da alaƙa, ana daidaita su a duk lokacin da zai yiwu tare da masu ba da gudummawa tukuna don tabbatar da tsarin garkuwar jikinsu kamar yadda zai yiwu.

Jagoran masu bincike a NYU Langone Health da Laura da Isaac Perlmutter Cibiyar Cancer, sabon binciken da ke gudana ya nuna cewa sabon tsarin maganin rigakafi, cyclophosphamide, abatacept, da tacrolimus, sun fi magance matsalar GvHD a cikin mutanen da ake yi wa magani. ciwon daji na jini.

"Sakamakon mu na farko ya nuna cewa yin amfani da abatacept a hade tare da sauran magungunan da ke hana rigakafi yana da lafiya kuma hanya ce mai mahimmanci don hana GvHD bayan dashen kwayar halitta don ciwon daji na jini," in ji mai binciken jagoran binciken da likitan jini Samer Al-Homsi, MD, MBA. "Alamomin GvHD tare da abatacept sun kasance kadan kuma galibi ana iya magance su. Babu wanda ya yi barazanar rayuwa, "in ji Al-Homsi, farfesa na asibiti a Sashen Magunguna a NYU Grossman School of Medicine da Perlmutter Cancer Center.

Al-Homsi, wanda kuma yake aiki a matsayin darekta na shirin dashen jini da bargo a NYU Langone da Perlmutter Cibiyar Ciwon daji, yana gabatar da sakamakon binciken kungiyar ta yanar gizo a ranar 13 ga watan Disamba a taron shekara-shekara na kungiyar American Society of Hematology a Atlanta.

Binciken ya nuna cewa a cikin manya guda 23 na farko da ke fama da cutar kansar jini da aka ba da tsarin maganin dashen dasawa na tsawon watanni uku, hudu kawai sun nuna alamun farko na GvHD, ciki har da kurjin fata, tashin zuciya, amai, da gudawa. Wasu halayen biyu sun haɓaka makonni bayan haka, galibi rashes na fata. Dukkansu an yi nasarar yi musu magani tare da wasu magunguna don alamun su. Babu wanda ya sami ƙarin bayyanar cututtuka, gami da lalacewar hanta ko wahalar numfashi. Duk da haka, majiyyaci ɗaya, wanda aka gaza dashensa, ya mutu sakamakon cutar sankarar bargo. Sauran (maza da mata 22, ko kashi 95) sun kasance marasa ciwon daji fiye da watanni biyar bayan dashen su, tare da gudummawar kwayoyin da ke nuna alamun samar da sababbin, lafiya, da ƙwayoyin jini marasa ciwon daji.

Tare da haɓaka zaɓuɓɓukan masu ba da gudummawa ga duk marasa lafiya, sakamakon binciken yana da yuwuwar magance rarrabuwar kabilanci a cikin juyewar kwayar halitta. Idan aka yi la'akari da yanayin tafkin masu ba da gudummawa zuwa yau, Baƙar fata, Amurkawa Asiya, da Hispanic ba su da ƙasa da kashi ɗaya bisa uku kamar yadda Caucasians ke iya samun mai ba da gudummawar kwayar tantanin halitta gaba ɗaya, barin membobin dangi a matsayin tushen mai ba da gudummawa mafi aminci. A halin yanzu an jera wasu Amurkawa 12,000 kuma suna jiran rajistar shirin bargon kashi na kasa, in ji Al-Homsi.

Binciken da aka yi a halin yanzu ya haɗa da dashen ƙwayoyin sel daga masu ba da gudummawa na kusa (rabi-mace) masu ba da gudummawa da marasa lafiya, gami da iyaye, yara, da ƴan’uwa, amma waɗanda tsarin halittarsu bai zama ɗaya ba, tare da haɗakar magungunan yana ƙara yuwuwar samun nasarar dasawa.

Sabon tsarin ya maye gurbin maganin mycophenolate mofetil da aka saba amfani da shi da abatacept. Al-Homsi ya ce abatacept ya kasance “mafi niyya” fiye da mycophenolate mofetil kuma yana hana ƙwayoyin T na rigakafi daga zama “a kunne,” matakin da ya dace kafin waɗannan ƙwayoyin rigakafi su iya kai hari ga wasu ƙwayoyin. An riga an yarda da Abatacept don magance wasu cututtuka na rigakafi, irin su amosanin gabbai, kuma an yi nasarar gwada shi ta hanyar hana GvHD tare da masu ba da gudummawar da ba su da alaƙa. Har ya zuwa yanzu, masu ba da gudummawa da suka dace sun nuna kyakkyawan sakamako a cikin rigakafin cutar da ba ta dace ba fiye da dangin da suka yi daidai da rabin dangi, ko abin da ake kira farin ciki, masu ba da gudummawa.

Har ila yau, a matsayin wani ɓangare na maganin da aka yi wa kwaskwarima, masu bincike sun rage lokacin jiyya na tacrolimus zuwa watanni uku, daga ainihin taga magani na watanni shida zuwa tara. Wannan ya faru ne saboda yuwuwar illolin mai guba na maganin akan koda.